Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery

Tata 1mg optimises e-commerce operations with Unicommerce

LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa

Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership

ekincare raises investment from MSD IDEA Studio Asia Pacific

ekincare has raised a total funding of $22M since 2015 till date

Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA

Pfizer Q1 2025 revenue drops 8% to $13.7 billion

Delivers robust earnings performance, successfully navigating a dynamic environment

We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer

Bayer expects 2025 to be the most difficult year of its turnaround